Aug 25, 2026 08:30AM
Aug 25, 2026 08:30AM
Jul 21, 2026 07:00AM
Jul 21, 2026 07:00AM
May 7, 2026 04:15PM
Apr 20, 2026 10:21AM
Apr 20, 2026 07:43AM Nektar Therapeutics reports positive 52-week data for alopecia areata drug trial
Apr 20, 2026 07:30AM
Mar 28, 2026 12:36PM
Mar 28, 2026 12:36PM
Mar 20, 2026 10:00AM
Mar 20, 2026 10:00AM
Mar 10, 2026 09:08AM
Feb 19, 2026 05:31PM Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight
Feb 17, 2026 07:00AM
Feb 16, 2026 05:31PM
Feb 10, 2026 07:01AM
Feb 10, 2026 07:00AM
Dec 16, 2025 07:30AM
Dec 16, 2025 07:30AM
Nov 8, 2025 05:45PM New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
Nov 6, 2025 04:15PM
Oct 22, 2025 08:00AM
Sep 18, 2025 08:46AM
Sep 18, 2025 08:45AM
Sep 9, 2025 07:00AM
Aug 7, 2025 04:15PM
Jul 29, 2025 09:01AM Nektar receives FDA fast track for alopecia areata treatment
Jul 29, 2025 09:00AM
Jun 24, 2025 07:31AM
Jun 24, 2025 07:30AM
May 8, 2025 04:15PM
Mar 12, 2025 04:15PM
Feb 26, 2025 07:01AM
Feb 26, 2025 07:00AM Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata
Feb 24, 2025 07:00AM
Feb 24, 2025 07:00AM
Feb 24, 2025 07:00AM
Feb 10, 2025 07:01AM
Feb 10, 2025 07:00AM
Dec 7, 2024 12:00PM
Nov 4, 2024 08:30AM Nektar Therapeutics (NKTR) to Sell Commercial PEGylation Reagent Manufacturing Business in Alabama
Nov 4, 2024 08:30AM
Mar 19, 2024 04:15PM
Jan 22, 2024 08:23AM
Dec 12, 2022 10:05AM
Apr 29, 2022 06:59AM
Apr 14, 2022 04:33PM
Apr 14, 2022 04:30PM Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab)
Mar 15, 2022 06:37AM

329,426 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All